Shares of Interpace Biosciences Inc. (IDXG) are up 20% in pre-market today, after the company announced that its subsidiary, Interpace Diagnostics, has entered into a contract with Avalon Healthcare Solutions, a specialty benefit management company with more than 3 million members, focused on laboratory testing. Terms remain undisclosed.
The new contract includes two of the Southeastern U.S.'s largest Blue Cross Blue Shield plans where members can now take advantage of the benefits of ThyGeNEXT and ThyraMIR thyroid testing while reducing their out of pocket expenses due to Interpace's status as an in-network provider.
Interpace has successfully achieved positive medical coverage for its services through Medicare as well as other leading national and regional health plans and is now focused on establishing more contracts to optimize the adjudication process.
The stock has been trading between $3.80 and $11.00 in the past one year, and closed Friday's trade at $5.00, down 89 cents or 15.11%. IDXG is currently trading at $6.00, up $1.00 or 20.00% in the pre-market trading session.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.